Article
Immunology
Thomas Krueger, Rebekka Wehner, Maik Herbig, Martin Kraeter, Michael Kramer, Jan Moritz Middeke, Friedrich Stoelzel, Catrin List, Katharina Egger-Heidrich, Raphael Teipel, Uta Oelschlaegel, Martin Wermke, Helena Jambor, Manja Wobus, Johannes Schetelig, Korinna Joehrens, Torsten Tonn, Julien Subburayalu, Marc Schmitz, Martin Bornhauser, Malte von Bonin
Summary: Functional impairment of the bone marrow niche, particularly a decrease in mesenchymal stromal cells (MSCs), is associated with cytopenia and graft failure after hematopoietic cell transplantation. Acute graft-versus-host disease (aGvHD) is shown to significantly reduce MSC numbers, and this reduction can be observed before clinical onset of aGvHD. The different phenotypic and functional characteristics of MSCs depending on the occurrence of aGvHD suggest that they may contribute to alloreactivity after transplantation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Qianqian Yu, Han Wang, Lingling Zhang, Wei Wei
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is commonly used to treat hematological malignancies and genetic diseases, with graft-versus-host disease (GVHD) being a common complication leading to severe morbidity and mortality. Current first-line therapeutic drugs for GVHD prevention and treatment are corticosteroids, but a significant number of patients develop steroid-refractory GVHD with poor prognosis. Various immune cells, such as Tregs, Bregs, and mesenchymal stromal cells (MSCs), have shown benefit in GVHD prevention and therapy, but further research is needed to optimize treatment strategies and improve patient prognosis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Yoshiyuki Tago, Chiho Kobayashi, Mineko Ogura, Jutaro Wada, Sho Yamaguchi, Takashi Yamaguchi, Masahiro Hayashi, Tomoyuki Nakaishi, Hiroshi Kubo, Yasuyoshi Ueda
Summary: The study found that human amnion-derived mesenchymal stem cells (AMSC) exhibit significant immunosuppressive effects and can delay the progression of acute graft-versus-host disease (GVHD) mainly by preventing T cell activation and proliferation through the PD-1 pathway.
SCIENTIFIC REPORTS
(2021)
Review
Immunology
Kilian Kelly, John E. J. Rasko
Summary: GvHD is a life-threatening complication of hematopoietic stem cell transplantation, often requiring high-dose corticosteroid treatment. MSCs show promise as a potential therapy due to their immunosuppressive and immunoregulatory effects, but their efficacy may be influenced by donor variability and manufacturing processes.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Cell & Tissue Engineering
Ying Li, Jie Hao, Zheng Hu, Yong-Guang Yang, Qi Zhou, Liguang Sun, Jun Wu
Summary: This study summarized 79 clinical trials involving the use of MSCs to prevent or treat GVHD, analyzing their characteristics and results. The researchers aimed to gain a comprehensive understanding of the progress, challenges, limitations, and future trends in the field, and provide new perspectives for the design of future trials.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Cell & Tissue Engineering
Weijiang Liu, Na Zhou, Yuanlin Liu, Wei Zhang, Xue Li, Yang Wang, Rongxiu Zheng, Yi Zhang
Summary: High expression of miR-223 in MSCs-Exo was found, and it could inhibit the adhesion and migration of T cells by targeting ICAM-1. Infusion of miR-223 Agomir alleviated clinical symptoms of aGvHD, reduced donor T cell infiltration, and lowered levels of inflammatory cytokines IFN-gamma, TNF-alpha, and IL-17.
STEM CELL RESEARCH & THERAPY
(2021)
Review
Biochemistry & Molecular Biology
Carl Randall Harrell, Valentin Djonov, Vladislav Volarevic
Summary: This review article summarizes the therapeutic effects and mechanisms of mesenchymal stem cells (MSC) and their exosomes (MSC-Exos) in the treatment of inflammatory eye diseases and ocular graft-versus-host disease (oGVHD).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Makoto Murata, Takanori Teshima
Summary: This article discusses the potential of MSC therapy in the treatment of acute GVHD, along with a comparison of studies on the two products, Remestemcel-L and Temcell. While Temcell's real-world efficacy was found to be equivalent to that observed in a prospective study, the precise position of Remestemcel-L/Temcell therapy in the treatment of acute GVHD remains to be determined.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Hui Li, Qi Liu, Xiaofeng Gao, Di Zhang, Shengjun Mao, Yongqian Jia
Summary: The study explored the potential of human umbilical mesenchymal stem cells transfected with IFN-γ gene and found that this treatment significantly reduced the incidence and severity of GVHD in vivo, providing a significant survival benefit.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Biochemistry & Molecular Biology
Jaspar Kloehn, Anne Kruchen, Kerstin Schuetze, Katharina Wustrau, Johanna Schrum, Ingo Mueller
Summary: Two pediatric patients underwent stem cell re-transplantation successfully, providing a new therapeutic option for steroid-refractory chronic graft-versus-host disease (SR-cGvHD).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Andrei Mircea Vacaru, Ana-Maria Mazilu, Madalina Dumitrescu, Ioana Madalina Fenyo, Anca Violeta Gafencu, Ana-Maria Vacaru
Summary: This study found that treatment with FasL-overexpressing MSC can improve GvHD and increase survival in mice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell & Tissue Engineering
Michaela Doering, Karin Melanie Cabanillas Stanchi, Katrin Lenglinger, Claudia Treuner, Friederike Gieseke, Annika Erbacher, Markus Mezger, Martin Vaegler, Paul-Gerhardt Schlegel, Johann Greil, Claudia Bettoni da Cunha Riehm, Christoph Faul, Michael Schumm, Peter Lang, Rupert Handgretinger, Ingo Mueller
Summary: Bone marrow-derived MSC treatment showed good efficacy in steroid-refractory GvHD, with a majority of patients achieving partial response and some achieving complete remission. Transplant-related mortality was associated with the treatment outcome.
STEM CELLS AND DEVELOPMENT
(2021)
Article
Cell & Tissue Engineering
Maria del Mar Macias-Sanchez, Cynthia Morata-Tarifa, Natividad Cuende, Ana Cardesa-Gil, Maria Angeles Cuesta-Casas, Maria Jesus Pascual-Cascon, Antonia Pascual, Carmen Martin-Calvo, Manuel Jurado, Jose Antonio Perez-Simon, Ildefonso Espigado, Sebastian Garzon Lopez, Gloria Carmona Sanchez, Rosario Mata-Alcazar-Caballero, Rosario Sanchez-Pernaute
Summary: Clinical trials using MSC therapy for GVHD have shown promising results, with a high overall response rate in patients. For patients with acute GVHD, age at the time of HSCT was found to be the only predictor inversely correlated with survival. Adverse events during treatment were reported but all resolved without long-term consequences, demonstrating the safety of MSC therapy.
STEM CELLS TRANSLATIONAL MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Mehrdad Hefazi, Sara Bolivar-Wagers, Bruce R. Blazar
Summary: This review provides the latest preclinical and clinical data on Treg cell therapy in the context of GVHD, highlighting the importance of T cell therapy in preventing and treating GVHD, and discussing future research directions and challenges.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Cell & Tissue Engineering
Ruonan Li, Jingke Tu, Jingyu Zhao, Hong Pan, Liwei Fang, Jun Shi
Summary: This study found that MSC co-transplantation is not an effective prophylactic option for SAA patients undergoing haplo-HSCT, suggesting that the general co-transplantation of MSCs for SAA haplo-HSCT recipients may lack evidence-based practice.
STEM CELL RESEARCH & THERAPY
(2021)